Press Releases

 

HEAT Study/HCC

  Date Title and Summary View
Oct 16, 2017
80+ Month Overall Survival (HR = 0.63, Pvalue = 0.02) Discussed in the 285 Patient Sub-group Treated with ThermoDox® plus Standardized Radiofrequency Ablation (sRFA) Ongoing Phase III OPTIMA Study to Confirm Hypothesis that the Combination of Standardized Radiofrequency Ablation Plus ThermoDox® May Substantially Increase Survival of ...
Nov 29, 2016
NIH Analysis of Data from Celsion's HEAT Study Reaffirms Correlation Between Increased RFA Burn Time per Tumor Volume and Significant Improvements in Overall Survival Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit for Patients Treated with ThermoDox® Plus Optimized RFA Compared with Optimiz...
Oct 31, 2016
LAWRENCEVILLE, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the presentation of data from the Company's HEAT Study, highlighting the curative potential for ThermoDox® plus optimized radiofrequency ablation (RFA) in intermediate primary liver cancer, also know...
Sep 12, 2016
Conclusions Drawn from Results of Celsion's HEAT Study Prompted NIH Analysis; Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit Compared to Treatment with RFA Alone Abstract Accepted for Oral Presentation at the 2016 RSNA Annual Meeting LAWRENCEVILLE, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) -- ...
Aug 15, 2016
Subgroup Data Continue to Show a Statistically Significant Improvement in Overall Survival, Consistent With a Two Year Median Survival Benefit Following Treatment with ThermoDox® plus Optimized RFA Data from the Chinese Cohort of Patients Show Clinically Meaningful Benefit LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion...
Jun 21, 2016
Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency Ablation (sRFA) Plus Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) May Substantially Increase Survival of Patients with HCC Compared to sRFA Alone LAWRENCEVILLE, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) toda...
Apr 26, 2016
LAWRENCEVILLE, N.J., April 26, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its ongoing global Phase III OPTIMA Study evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combi...
Aug 6, 2015
LAWRENCEVILLE, N.J., Aug. 6, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiof...
Feb 23, 2015
LAWRENCEVILLE, N.J., Feb. 23, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liv...
Jul 28, 2014
LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary li...
Page:
1
NextLast
= add release to Briefcase
Share This